Glaukos unveils licensing agreement for compounds that target Demodex mites
September 20th 2021Glaukos has entered into a licensing agreement with Attillaps Holdings Inc., giving it an exclusive license to research, develop, manufacture and commercialize Attillaps’ proprietary library of investigational pharmaceutical compounds that target the eradication of Demodex mites.
Considering keratoconus-like changes after DMEK in Fuchs' dystrophy
September 20th 2021A retrospective review was performed to describe changes in corneal thickness and to identify the incidence of posterior corneal changes characteristic of keratoconus, following DMEK surgery. Here’s what investigators found.